Agenda
Applications for consideration at this meeting
- 1516 Testing for epidermal growth factor receptor (EGFR) status in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) to determine eligibility for osimertinib
- 1554 Testing of tumour tissue or blood to detect somatic or germline BRCA1 or BRCA2 gene mutations, in a patient with newly diagnosed, advanced (FIGO stage III-IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to first-line platinum-based chemotherapy)
- 1559 Endoscopic Mucosal Resection
- 1569 Chitosan-based cartilage biomatrix implant (BST-CarGel), in conjunction with the marrow stimulation technique (microfracture), for repair of focal cartilage defects
- 1573 Reproductive carrier screening for fragile X syndrome, spinal muscular atrophy and cystic fibrosis
- 1575 Autologous fat grafting (AFG) by injection, for defects arising from breast surgery, cancer treatment/prevention or congenital deformity
- 1577 Autologous fat grafting (AFG) by injection, for treatment of burn scars, and treatment of facial defects due to craniofacial abnormalities
- 1582 Detection of Aquaporin-4 (AQP4) antibodies in serum of cerebrospinal fluid for diagnosis of Neuromyelitis optica (NMO)
- 1586 Transurethral water vapour ablation for the treatment of benign prostatic hyperplasia
- 1590 Review of immunoglobulin use for multifocal motor neuropathy
- 1593 Bovine bioinductive collagen implant for repair of rotator cuff tear
- 1610 Clostridium botulinum type A toxin-haemagglutin complex (Dysport) for the treatment of moderate to severe upper-limb spasticity due to cerebral palsy
- 1612 Prostatic urethral lift procedure for men with benign prostatic hyperplasia
- 1622 Cardiac ablation devices for use in ventricular arrhythmia and supraventricular tachycardia
- 1623 Voretigene neparvovec (Luxturna) for the treatment of biallelic RPE-65-mediated Inherited Retinal Dystrophies
- 1624 17p deletion testing for access to acalabrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
- 1625 Dinutuximab beta for high-risk neuroblastoma
Related information
Committee: